Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD)Approval is based on comprehensive analytical, non-clinical and clinical similarity data, including a confirmatory efficacy study…

European Commission approves aflibercept biosimilar Mynzepli

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration

Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD) Approval is based on comprehensive analytical, non-clinical and clinical similarity data, including a confirmatory efficacy study comparing Mynzepli® with the reference biologic Eylea® in patients with neovascular AMD REYKJAVIK, Iceland […] The post Adv…